Join to View Full Profile
Roswell Park Comprehensive Cancer CenterElm and Carlton StreetBuffalo, NY 14263
Phone+1 716-845-3239
Fax+1 716-845-8261
Dr. Wong is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Michael Wong is an oncology specialist based in Buffalo, NY, with a focus on melanoma, rare skin cancers and novel therapeutics. He completed his medical education at the University of Toronto Faculty of Medicine in 1989. Currently, he serves as the Physician in Chief at Roswell Park Comprehensive Cancer Center. Dr Wong was previously professor at the University of Texas M.D. Anderson Cancer Center and Medical Executive for Integration and Special Programs for the MD Anderson Network. Dr. Wong was also the Adams Endowed Chair in Cancer Research, and Head of Solid Tumor Division at the University of Southern California. He is an expert in Drug Development including Small Molecules, Cytokines, Checkpoint Inhibitors and Oncolytic Vaccines. His clinical practice includes Melanoma, Merkel Cell Carcinoma, and other rare skin cancers.
Education & Training
University of Toronto Faculty of MedicineClass of 1989
Certifications & Licensure
FL State Medical License 2021 - Present
NY State Medical License 2003 - 2026
TX State Medical License 2016 - 2026
CA State Medical License 2010 - 2024
OK State Medical License 2020 - 2021
PA State Medical License 1998 - 2004
American Board of Internal Medicine Medical Oncology
Clinical Trials
Publications & Presentations
PubMed
- Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma.Merve Hasanov, Simin Kiany, Marie-Andrée Forget, Roland Bassett, Michael A Davies
Oncoimmunology. 2025-12-01 - Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors.Mohammed M Milhem, Trisha M Wise-Draper, Sunandana Chandra, Glenn J Hanna, Douglas E Laux
Journal for Immunotherapy of Cancer. 2025-07-25 - Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.Elizabeth M Burton, Denái R Milton, Michael T Tetzlaff, Khalida Wani, Merrick I Ross
Journal of Clinical Oncology. 2025-07-10
Press Mentions
Newsweek Names Roswell Park to America's Best Cancer Hospitals ListJune 6th, 2025- Report: Cancer Deaths Down, Some Groups See Increased Incidence RatesApril 25th, 2025
- Encouraging Results After Discontinuation of Cancer Immunotherapy Due to Immune AEsApril 18th, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
